Intracellular signal transduction pathway proteins as targets for cancer therapy

被引:133
作者
Adjei, AA
Hidalgo, M
机构
[1] Mayo Clin, Coll Med, Dept Oncol, Div Med Oncol, Rochester, MN 55905 USA
[2] Mayo Fdn, Dept Oncol, Rochester, MN USA
[3] Johns Hopkins Univ Hosp, Sidney Kimmel Canc Ctr, Baltimore, MD 21287 USA
关键词
D O I
10.1200/JCO.2005.23.648
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating cytokines, hormones, and growth factors control all aspects of cell proliferation, differentiation, angiogenesis, apoptosis, and senescence. These chemical signals are propagated from the cell surface to intracellular processes via sequential kinase signaling, arranged in modules that exhibit redundancy and cross talk. This signal transduction system comprising growth factors, transmembrane receptor proteins, and cytoplasmic secondary messengers is often exploited to optimize tumor growth and metastasis in malignancies. Thus, it represents an attractive target for cancer therapy. This review will summarize current knowledge of selected intracellular signaling networks and their role in cancer therapy. The focus will be on pathways for which inhibitory agents are currently undergoing clinical testing. Original data for inclusion in this review were identified through a MEDLINE search of the literature. All papers from 1966 through March 2005 were identified by the following search terms: "signal transduction," "intracellular signaling," "kinases," "proliferation," "growth factors," and "cancer therapy." All original research and review papers related to the role of intracellular signaling in oncogenesis and therapeutic interventions relating to abnormal cell signaling were identified. This search was supplemented by a manual search of the Proceedings of the Annual Meetings of the American Association for Cancer Research, American Society of Clinical Oncology, and the American Association for Cancer Research (AARC) -European Organisation for Research and Treatment of Cancer (EORTC) -National Cancer Institute (NCI) Symposium on New Anticancer Drugs.
引用
收藏
页码:5386 / 5403
页数:18
相关论文
共 179 条
  • [1] Identification of TOR signaling complexes: more TORC for the cell growth engine
    Abraham, RT
    [J]. CELL, 2002, 111 (01) : 9 - 12
  • [2] Adams J, 1999, CANCER RES, V59, P2615
  • [3] Blocking oncogenic Ras signaling for cancer therapy
    Adjei, AA
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14): : 1062 - 1074
  • [4] Adjei Alex A, 2003, Cancer Chemother Biol Response Modif, V21, P127
  • [5] New agent overcomes resistance to imatinib
    Ahamd, K
    [J]. LANCET ONCOLOGY, 2005, 6 (03) : 137 - 137
  • [6] Depletion of p185(erbB2), Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity
    An, WG
    Schnur, RC
    Neckers, L
    Blagosklonny, MV
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (01) : 60 - 64
  • [7] [Anonymous], 2005, MED LETT DRUGS THER, V47, P25
  • [8] Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
    Ashar, HR
    James, L
    Gray, K
    Carr, D
    Black, S
    Armstrong, L
    Bishop, WR
    Kirschmeier, P
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (39) : 30451 - 30457
  • [9] ATKINS MB, 2004, UROL ONCOL, V22, P431
  • [10] RAS GENES
    BARBACID, M
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 : 779 - 827